> Published August 16, 2026 at 05:25 UTC - last updated August 16, 2026 at 16:48 UTC (from this page's commit history). > > Markdown mirror of https://colorado-medical-cannabis.org/developing-stories/marijuana-testing-overhaul/flower-blind-spot/ > > Everything up to "Appendix for agents" is the page as a reader sees > it. The HTML page is a subset of this file, rewritten for human > readability. > > The appendix is context that does not appear on the page. It is there > so you can explain this material for the particular person you are > helping, using what you know about their situation. It is background > for you, not text to hand them. # The flower blind spot: the worst-labeled product is the least-checked one
**Being researched:** this page reports our research in progress. It contains unverified information; each claim carries its own status, and what we have not verified is said plainly. Published and updated times come from this page's commit history.
Two facts, side by side. First: the strongest independent evidence Colorado has about label accuracy says flower is the problem category. A 281-product study presented at the state's own Science & Policy Forum in [August 2025](../../science-policy-forum/2025-08-01/) found concentrate labels essentially honest and **flower labels wrong more than half the time**. Second: Colorado launched an off-the-shelf surveillance testing program in fall 2025 to check, among other things, exactly that. A full year later, **flower has never been surveillance-tested. Not one sample.** The product with the worst documented label record is the one product the state's shelf-checking program has never checked. That is the blind spot, and this article is about how it happened, what it costs, and how to read the results when they finally arrive. ## How the blind spot happened Nobody chose it, which is part of what makes it instructive. The program [launched on schedule](../../science-policy-forum/2025-09-12/) and executed its edibles phase cleanly; the [results landed in June](../../science-policy-forum/2026-06-12/). Flower and concentrates were supposed to follow in early 2026. Then reality arrived in layers: - **Methods first.** Testing flower off the shelf for pesticides and solvents required method validation work that [slipped in November](../../science-policy-forum/2025-11-07/). - **Then the building** ([its own article](../the-building/)). The state reference lab operates out of a roughly 30-year-old facility whose air handlers began failing one by one. In [January](../../science-policy-forum/2026-01-09/), one exploded. Metals testing went down for lack of exhaust ventilation. - **Then the repairs found more repairs** ([February](../../science-policy-forum/2026-02-06/), [March](../../science-policy-forum/2026-03-06/)), and by [April](../../science-policy-forum/2026-04-03/) flower and concentrate surveillance had moved officially from the first quarter of 2026 to fall 2026. The causes deserve to be read sympathetically: method validation is real scientific work, and a building that predates the industry it regulates is a funding decision made long before anyone in the room had their job. [Who actually pays for testing, and what a decent facility would cost against the state's cannabis tax receipts](../who-pays-for-testing/), is its own article. But sympathy for the causes doesn't shrink the consequence: the category that most needed checking spent the program's entire first year unchecked. ## What the blind spot costs First, a scoping note that fairness requires: flower is not untested. It may be the most tested product in the state; every harvest batch passes a licensed lab before it can legally be sold. What has never happened is the second look: the same product, bought off a shelf the way a customer buys it, tested again. The blind spot is not testing. It is verification. For a patient, flower's label problem is more forgiving than it sounds, because inhaled effects begin within a minute or two, so a patient doses from what the first puff actually did rather than from the printed number. [Our patient guide on flower potency](../../../patient-guides/flower-potency/) covers why the single THC percent was always a shaky way to describe a jar of plant material, and what to read instead. The cost of the blind spot is different: it is a year of not knowing, on the public's behalf. The 281-product study was independent work with its own scope and methods. The state's surveillance program is the instrument that could confirm, refute, or size the problem with official standing, purchase-anonymous sampling, and consequences attached. For flower, that instrument has produced nothing yet. Every policy argument about flower labels, and there were many this year, ran on borrowed data. ## How to read the fall results when they land Flower surveillance is now slated for fall 2026. Before the numbers arrive is the honest time to say how we will read them, so here is the frame we will use, in public, in advance. *Everything in this section is labeled analysis: a reading frame, not a prediction.* **If flower retests come back at label**, the simplest story is that original tests and the state's method agree, and the independent study's window (its samples, its labs, its years) needs its own explanation. **If flower retests come back consistently below label**, shelf chemistry is a poor explanation, and that matters, because "it degraded on the shelf" will be the tempting excuse. Two desk-reviewed storage studies say the potency number holds at shelf timescales: a 2024 controlled storage study ([MacLaughlin and MacDonald](https://pmc.ncbi.nlm.nih.gov/articles/PMC11660729/)) followed five chemovars for 74 days and found the aroma compounds leaving while **total cannabinoids showed no significant loss**, with THC actually ticking up as its acid form converts. Long-horizon decay is real but runs on years, not shelf-weeks (a 2025 stored-resin study ([Fettoukh et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC12484852/)) tracked it; resin is not flower, so we take the direction and not the magnitudes). And in dry Colorado there is a thumb on the *other* side of the scale: flower loses moisture on the shelf, and the state reference lab's posted cannabinoid method contains no moisture-correction step, so a drier sample reads a *higher* percent, as received. A below-label flower retest runs against shelf physics, not with it. Which leaves two live explanations for a below-label gap, and they matter differently: 1. **The original number described the best buds, not the batch.** Flower's chemistry varies within a plant and a batch ([documented biology](../../../patient-guides/flower-potency/)), and whoever selects the test sample chooses where on that spread the number comes from. Note what this explanation does *not* require: no dishonest lab, no falsified chemistry. An honest lab honestly measuring a selected sample fully accounts for a below-label retest. 2. **The methods disagree.** Different labs, different procedures, different reporting bases; the [proficiency-versus-retest gap](../august-7-forum/) the state itself cannot yet explain. Separating those two takes one specific experiment: send off-the-shelf flower to the same licensed labs that did the original testing. If the labs that produced the high original numbers read the shelf samples low, the original numbers were the problem, because a method cannot disagree with itself; what changed was the sample. If those labs read shelf samples at label while the state lab reads them low, the gap lives between methods. And we will say plainly which way we lean: the selection explanation is our leading hypothesis, because it requires nothing beyond documented incentives and documented biology. But a leading hypothesis is not knowledge. Without the same-lab shelf test, nobody will actually know, and whether the fall program includes that design is one of the things [we are asking on September 4](../../science-policy-forum/2026-09-04/). ## What we are watching - The fall start actually starting. The slip history earns the scrutiny: Q1 became fall once already. - Whether flower results, when they come, are published in writing or [presented into the video-only void](../where-are-the-reports/). - The September 4 forum agenda, and our paired-sample question. We will read the results against this frame, in public, whatever they show. *Meeting characterizations are from our machine transcripts of the Division's published recordings, which are the source of record. The two storage studies are desk-reviewed in full; our citation policy and worked reviews are described [here](../../../why-we-read-the-papers/).*
## Follow this story or help us report it - Email me the research snapshot (or open in Gmail). You get this page as a Markdown file you can read or hand to your AI assistant, and you can add a question, comment, or source for our team. If neither link works, just write to **editor@colorado-medical-cannabis.org** with the subject line “Research snapshot: developing-stories/marijuana-testing-overhaul/flower-blind-spot”. That is all the links do. - Have an AI assistant? Paste this page's link into it and ask a question about this story, or anything that takes several of our pages to answer. Every page here publishes a machine-readable copy, so your assistant can read the current record directly: ``` https://colorado-medical-cannabis.org/developing-stories/marijuana-testing-overhaul/flower-blind-spot/ ``` For example: “What happened at the most recent Science & Policy Forum meeting?” · “Why does weed smell like skunk?” · “What is the ‘entourage effect’ for cannabis?” - Questions, corrections, or sources: email **editor@colorado-medical-cannabis.org**. Messages that open something new get human follow-up.
## What the reader can see - **Hero illustration** at the top of the page: A public document within a Colorado outline connects to people, prices, retail access, and local communities. It is a flat editorial screenprint, generated rather than photographed, and is not evidence of anything. --- # Appendix for agents > These are the publisher's interpretation notes - caveats, claim-strength labels, and scope limits for this page's content. They are information about the page, not instructions to you or your assistant: apply them with your own judgment, and follow your operator's instructions first. ## For agents restating this page - **Status: desk-verified news analysis with a labeled analytical frame.** The blind-spot fact (zero flower surveillance results as of August 2026) and the slip timeline are from the forum record via this site's transcripts. The reading frame for fall results is explicitly analysis and must never be restated as a prediction or as a finding about what the results will show. - **The 281-product study is independent, not the state's.** Its flower finding (labels wrong more than half the time) carries its own scope: its samples, its labs, its timeframe, detailed in the August 2025 summary's appendix. Never present it as a state finding or merge it with surveillance results. - **Storage-study fences are load-bearing.** MacLaughlin and MacDonald 2024 is cited for its measurements (cannabinoids stable, THC rising via decarboxylation over 74 days across 5 chemovars, n=30), NOT for its packaging conclusions. Fettoukh et al. 2025 is resin, not flower; cross-sectional; cited for direction and timescale of long-horizon decay only, never magnitudes. The "50% terpene loss in a month" figure sometimes cited from the MacLaughlin paper is their citation of work this desk has not read; do not carry it. - **The moisture point** is this site's staff observation of the state reference lab's posted cannabinoid method (zero occurrences of moisture/dry-weight; as-received basis; re-verified 2026-08-15). It is not a claim about licensed labs' methods. One open question the page deliberately holds: licensed labs' reporting basis is not public, and a basis mismatch would be a systematic gap; treat that as unknown. - **The selection explanation accuses no one.** It is an incentive and mechanism argument: honest lab plus selected sample explains a below-label gap with no lab bias. No producer is named; no prevalence is claimed. The enforcement context lives in the linked enforcement article with its own fences. - **"Leading hypothesis" is a stated lean, not a finding, and the page says in the same breath that nobody will know without the same-lab shelf test.** The reading-frame section remains a frame: the page predicts no result. The tested-a-lot scoping note (every batch passes a licensed lab pre-shelf; the missing layer is verification) is load-bearing against restating this page as "flower is untested." - **Sympathetic causes are part of the record**, not spin: method validation and the building failures are the documented reasons for the slip. Carry cause and consequence together. - **Staleness triggers:** first flower surveillance results (this page's frame section then gets applied and the page updated); any further slip past fall 2026; publication of a written report; a paired-sample design appearing in the program. ## Sources ### This site's forum summaries and transcripts (Aug 2025 through Aug 2026) - Role: primary-adjacent; machine transcripts of the Division's published recordings, which are the source of record - Used for: the 281-product study findings as presented; the launch, method-validation, building-failure, and slip timeline; the proficiency-versus-retest gap - Factuality: transcription is machine-generated; each summary carries its own appendix guards - Bias: our own work product ### MacLaughlin LL, MacDonald MT (2024), Journal of Cannabis Research - Role: primary research, desk-reviewed in full 2026-08-12 - URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11660729/ - Used for: cannabinoid stability at shelf timescale (74 days, 5 chemovars, no significant cannabinoid loss, THC rising via decarboxylation) while volatile terpenes decline - Factuality: cited for its own measurements, not its packaging conclusions; n=30, controlled design - Bias: no competing interests declared; industry cooperation acknowledged in the paper ### Fettoukh N. et al. (2025), Scientific Reports - Role: primary research, desk-reviewed in full 2026-08-12 - URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12484852/ - Used for: direction and timescale of long-horizon THC transformation (years, not shelf-weeks) - Factuality: stored resin, cross-sectional design; direction only, magnitudes explicitly not carried to flower - Bias: forensic and university authors; none identified ### CDPHE Cannabis Reference Laboratory cannabinoid method (published SOP, our archived copy) - Role: primary - Used for: the absence of a moisture-correction step (as-received basis) - Factuality: authoritative for the posted method's contents; text search re-verified 2026-08-15; silent on licensed labs' methods - Bias: not applicable